LumiraDx Ltd
NASDAQ:LMDX
LumiraDx Ltd
NASDAQ:LMDX
Price:
0.016 USD
Market Closed
Updated:
May 6, 2024
LumiraDx Ltd
Operating Income
|
LumiraDx Ltd
Operating Income Peer Comparison
Comparables:
SN
LIVN
EKF
AGL
CREO
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
LumiraDx Ltd
NASDAQ:LMDX
|
Operating Income
-$225.1m
|
CAGR 3-Years
-25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Smith & Nephew PLC
LSE:SN
|
Operating Income
$763m
|
CAGR 3-Years
14%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Operating Income
$57m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Operating Income
£4.9m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
7%
|
|
|
Angle PLC
LSE:AGL
|
Operating Income
-£24.5m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Operating Income
-£30.8m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is LumiraDx Ltd's Operating Income?
Operating Income
-225.1m
USD
-225.1m
USD
Based on the financial report for Dec 31, 2022, LumiraDx Ltd's Operating Income amounts to -225.1m USD.
What is LumiraDx Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
-25%
-25%
Over the last year, the Operating Income growth was -106%. The average annual Operating Income growth rates for LumiraDx Ltd have been -25% over the past three years .
You don't have any saved screeners yet
